Handheld Device Improves Toxicity Data Collection

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 6
Volume 11
Issue 6

Wireless tablet-sized computers and user-friendly software may soon be helping investigators collect clinical trials toxicity data. A new handheld prototype with all the capabilities of a standard laptop computer was demonstrated at the LENT IV workshop.

Wireless tablet-sized computers and user-friendly software may soon be helping investigators collect clinical trials toxicity data. A new handheld prototype with all the capabilities of a standard laptop computer was demonstrated at the LENT IV workshop.

"The software guides the user through data entry for patient registration, prestudy, during study treatment, and follow-up," explained Kamal Narang, vice president of software development services for Capital Technology Information Services, Inc., a health informatics company from Rockville, Maryland, that is developing the software.

Dr. Andy Trotti also has contributed to the software design. "The software will help the user find and code any CTC toxicity criteria by using a ‘directed data collection approach,’" Dr. Trotti said.

The software presents to the user a study-specific list of adverse effects recommended for screening based on the type of study being conducted. For example, a patient treated for lung cancer with radiation and chemotherapy will need to be screened for thoracic organ injury as well as the adverse effects expected of the specific drugs in the protocol.

The software will also recognize that adverse effects seen in follow-up are often different than those seen during active treatment, and will adjust the recommended list of adverse events to include late effects.

Mr. Narang commented: "This approach can also be adapted for surgically oriented studies or even for general outcomes data collection in standard clinical practice. We are designing it with maximum flexibility to match the needs of the user."

The system also can perform data analysis or export the data to the NCI or other groups. It will also prompt the user to submit an adverse event report to regulatory authorities based on reporting requirements.

Related Videos
Amrita Y. Krishnan, MD, and Binod Dhakal, MD
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
A panel of 4 experts on multiple myeloma
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"
Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Related Content